Prevention of Nausea and Vomiting Secondary to FOLFIRINOX Chemotherapy in Gastrointestinal Cancer Patients

Trial Profile

Prevention of Nausea and Vomiting Secondary to FOLFIRINOX Chemotherapy in Gastrointestinal Cancer Patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2018

At a glance

  • Drugs Fosaprepitant (Primary) ; Dexamethasone; Fluorouracil; Irinotecan; Ondansetron; Oxaliplatin
  • Indications Nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Apr 2018 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.
    • 15 Apr 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Jun 2018.
    • 21 Aug 2017 Planned End Date changed from 1 Apr 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top